Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Thoracic Cancer|January 27, 2024
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancerLi-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, et al.
Cancer Medicine|February 27, 2026
Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational StudyPing-Chih Hsu, How-Wen Ko, Li-Chung Chiu, et al.
Thoracic Cancer|April 17, 2025
Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinibZi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, et al.
Oncology Letters|March 12, 2025
Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasisChen-Chuan Hsu, Li-Chung Chiu, How-Wen Ko, et al.
Thoracic Cancer|April 6, 2019
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancerChih-Hsi Scott Kuo, Chin-Chou Wang, Yu-Chen Huang, et al.
Cancers|July 27, 2022
Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with DenosumabHow-Wen Ko, Chi-Tsun Chiu, Chih-Liang Wang, et al.
Therapeutic Advances in Medical Oncology|June 29, 2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysisPing-Chih Hsu, How-Wen Ko, Li-Chung Chiu, et al.
Oncotarget|December 13, 2017
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutationsChien-Ying Liu, Chih-Liang Wang, Shih-Hong Li, et al.
Targeted Oncology|March 21, 2026
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT StudyHow-Wen Ko, Ying-Ting Liao, Sheng-Kai Liang, et al.
European Journal of Medical Research|January 28, 2025
Ventilatory variables and computed tomography features in COVID-19 ARDS and non-COVID-19-related ARDS: a prospective observational cohort studyLi-Chung Chiu, Hsin-Hsien Li, Yu-Hsiang Juan, et al.
Pageof 5